268 related articles for article (PubMed ID: 34019712)
21. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.
Davit B; Braddy AC; Conner DP; Yu LX
AAPS J; 2013 Oct; 15(4):974-90. PubMed ID: 23821352
[TBL] [Abstract][Full Text] [Related]
22. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.
Nair AK; Anand O; Chun N; Conner DP; Mehta MU; Nhu DT; Polli JE; Yu LX; Davit BM
AAPS J; 2012 Dec; 14(4):664-6. PubMed ID: 22718306
[TBL] [Abstract][Full Text] [Related]
23. Converging Generic Drug Product Development: Bioequivalence Design and Reference Product Selection.
Charoo NA
Clin Pharmacokinet; 2020 Nov; 59(11):1335-1355. PubMed ID: 32757104
[TBL] [Abstract][Full Text] [Related]
24. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products.
Renukuntla J; Palakurthi SS; Bolla PK; Clark BA; Boddu SHS; Manda P; Sockwell S; Charbe NB; Palakurthi S
Int J Pharm; 2022 Nov; 627():122209. PubMed ID: 36162609
[TBL] [Abstract][Full Text] [Related]
25. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
[TBL] [Abstract][Full Text] [Related]
26. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
Somayaji MR; Das D; Przekwas A
Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
[TBL] [Abstract][Full Text] [Related]
27. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
[TBL] [Abstract][Full Text] [Related]
28. Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence Studies.
Kajiwara E; Kamizato H; Shikano M
Ther Innov Regul Sci; 2021 Sep; 55(5):1096-1100. PubMed ID: 34097289
[TBL] [Abstract][Full Text] [Related]
29. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
[TBL] [Abstract][Full Text] [Related]
30. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe.
Limberg J; Potthast H
Biopharm Drug Dispos; 2013 Jul; 34(5):247-53. PubMed ID: 23585295
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
32. International harmonization of bioequivalence studies and issues shared in common.
Nakai K; Fujita M; Ogata H
Yakugaku Zasshi; 2000 Nov; 120(11):1193-200. PubMed ID: 11190204
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system.
Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406
[TBL] [Abstract][Full Text] [Related]
34. The new European Medicines Agency guideline on the investigation of bioequivalence.
Morais JA; Lobato Mdo R
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
[TBL] [Abstract][Full Text] [Related]
35. Application of the biopharmaceutical classification system in clinical drug development--an industrial view.
Cook J; Addicks W; Wu YH
AAPS J; 2008 Jun; 10(2):306-10. PubMed ID: 18500563
[TBL] [Abstract][Full Text] [Related]
36. Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission.
Cardot JM; Garcia-Arieta A; Paixao P; Tasevska I; Davit B
Eur J Pharm Sci; 2018 Jan; 111():399-408. PubMed ID: 29032306
[TBL] [Abstract][Full Text] [Related]
37. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.
Kollipara S; Martins FS; Sanghavi M; Santos GML; Saini A; Ahmed T
J Pharm Sci; 2024 Feb; 113(2):345-358. PubMed ID: 38043684
[TBL] [Abstract][Full Text] [Related]
38. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
39. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.
Plöger GF; Quizon PM; Abrahamsson B; Cristofoletti R; Groot DW; Parr A; Langguth P; Polli JE; Shah VP; Tajiri T; Mehta MU; Dressman J
J Pharm Sci; 2020 Jun; 109(6):1846-1862. PubMed ID: 32240696
[TBL] [Abstract][Full Text] [Related]
40. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
Mayers I; Bhutani M
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
